Baylor Residual breast cancer
13 Nov 2014 | | Contributor(s):: Creighton C, Lewis M, Chang J, Jonathan Bistline
Residual breast cancers after conventional therapy display mesenchymal as tumor-initiating features. There are four (4) files included in this study: Sample Annotation (combined_sample_annotation.txt) Gene expression data from CD44+/CD24- cells sorted by flow cytometry (GSE7513.gct) Human...
Breast Cancer Crossword
20 Nov 2015 | | Contributor(s):: Katelyn Schifano
This crossword is designed for use in social media as well as patient waiting areas.
Integrated analysis of breast cancer cell lines reveals unique signaling pathways
16 Sep 2014 | | Contributor(s):: Laura M Heiser, Nicholas J Wang, Carolyn L Talcott, Keith R Laderoute, Merrill Knapp, Yinghui Guan, Zhi Hu, Safiyyah Ziyad, Barbara L Weber, Sylvie Laquerre, Jeffrey R Jackson, Richard F Wooster, Wen Lin Kuo, Joe W Gray, Paul T Spellman
AbstractBackgroundCancer is a heterogeneous disease resulting from the accumulation of genetic defects that negatively impact control of cell division, motility, adhesion and apoptosis. Deregulation in signaling along the EgfR-MAPK pathway is common in breast cancer, though the manner in which...
Integrative Cancer Biology Program Datasets
26 Apr 2016 | | Contributor(s):: Jonathan Bistline, Michael Reich
The NCI-ICBP promotes an integrative/systems approach to the study of cancer biology. The Program encourages scientists to study cancer as a complex biological system. Information gained from these studies are used to build reliable and testable predictive computation models of cancer processes...
LBL ICBP50 integrative genomic data
13 Nov 2014 | | Contributor(s):: Joe Gray, Jonathan Bistline
From Joe Gray, Lawrence Berkeley National Laboratory. There are seventeen (17) files in this study: Affymetrix U133A gene expression data (icbp_u133a.gct) Affymetrix U133A gene expression data (ICBP_U133a.zip) Affymetrix splice junction exon-exon data (ICBP_Junction.zip) Affymetrix...
Screening for Small Molecules: Target Discovery Against miRNAs for Breast Cancer Treatment
18 Aug 2015 | | Contributor(s):: Odemaris Narvaez del Pilar
Breast cancer is one of the leading causes of cancer related deaths and morbidity among women worldwide. Identifying new targets and developing new therapies is very important in order to improve patient outcomes and minimize this health burden. MicroRNAs, a type of non-coding RNA, are potential...